Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

nder)20112010

2010

2011

2010

2010Zyprexa®

$1,182.3$1,212.7(3)%$3,872.4$3,690.65%Cymbalta®

1,068.6825.329%2,980.82,496.219%Alimta

629.7560.312%1,823.01,639.511%Humalog®

593.2494.020%1,705.51,505.113%Cialis

469.8406.516%1,381.41,233.512%Humulin®

301.5278.08%903.2801.013%Evista®

270.1256.85%799.7757.96%Forteo®

240.3199.720%687.3603.814%Strattera

153.2127.920%449.5421.37%Gemzar

91.0324.6(72)%359.5905.8(60)%Animal Health

451.0353.228%1,210.4967.025%Total Revenue

$6,147.9$5,654.89%$18,239.9$16,889.08%Zyprexa

In the third quarter of 2011, Zyprexa sales totaled $1.182 billion, a decrease of 3 percent compared with the third quarter of 2010.  U.S. sales of Zyprexa decreased 7 percent to $563.2 million, driven by lower volume, partially offset by higher net effective selling prices. Zyprexa sales in international markets increased 2 percent, to $619.1 million, driven primarily by the favorable impact of foreign exchange rates, partially offset by lower prices and lower volume. The company lost patent exclusivity for Zyprexa in most of Europe in September 2011 and will lose exclusivity in the U.S. on October 23, 2011. While it is difficult to predict the precise timing and magnitude of the impact on Zyprexa sales, the company expects the introduction of generics to result in a rapid and severe decline in Zyprexa sales.  

Cymbalta

For the third quarter of 2011, Cymbalta generated $1.069 billion in revenue, an increase of 29 percent compared with the third quarter of 2010. U.S. sales of Cymbalta increased 26 percent, to $809.5 million, driven by increased prices and higher demand. Revenue outside the U.S. was $259.1 million, an increase of 42 percent, driven primarily by higher demand in international markets and, to a lesser extent, the favorable impact of foreign exchange rates.

Alimta

For the
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Declares Fourth-Quarter 2011 Dividend
2. Lilly Announces Changes in Senior Management
3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
7. Lilly Health Channel Debuts on YouTube
8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, ... agreement with KRS Global Biotechnology, Inc. for the compounding, packaging ... compounded for shipment in the United States ... approved Outsourcing Facility capable of compounding naltrexone tablets in various ...
(Date:1/23/2015)... , Jan. 23, 2015  HyGreen, Inc., a leader ... and partnership with RCA Medical, a subsidiary of Ascendis ... . Each year, hundreds of millions of ... infections as organisms are transmitted from patient to patient ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... 2007 /PRNewswire/ -- Once-daily,dosing with Otsuka's investigational ... associated with improvements,in signs and symptoms of ... receiving conventional care, without an,adverse effect on ... from the short- and long-term analyses of ...
... Stent Technology Holds Promise as,Future-Generation Treatment Option ... ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ ... the world's,first clinical trial evaluating the overall ... eluting stent platform for the,treatment of coronary ...
Cached Medicine Technology:Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 2Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 3
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
(Date:12/26/2014)... The US represents the largest market for ... GlobalData’s forecast estimates that sales of branded therapies were $2.23 ... the high incidence of the disease, high drug treatment rate, ... China. Increased sales of CRC therapies over the forecast period ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... http://www.nhs.uk ), the,digital ,front door, to the NHS launches ... both the physical and financial cost of smoking in ... interactive calculator,( http://www.nhs.uk/Tools/Pages/Smoking.aspx ) enables users to not only ... much you could save over,one to ten years - ...
... 11 In this 90 minute episode, Dr. Drew,reunites several ... they left treatment. Drew reveals who has relapsed, who has ... is comprised of,recovering addicts and fans of the show, will ... happened over the season., (Photos: ...
... as whole grains cuts risk of cerebral infarction , , ... magnesium-rich foods such as whole grains may reduce male ... flow to the brain is blocked, a new Swedish ... Stockholm analyzed the diets and other health/lifestyle habits and ...
... March 11 Perrigo Company,(Nasdaq: PRGO ; TASE) ... U.S. Food and Drug Administration (FDA) for its Abbreviated ... The product is a topical corticosteroid indicated for the ... for the brand, Olux(R),Foam, 0.05%, were approximately $85 million ...
... 11 Verathon(R) is pleased to,announce a new ... 9400,bladder volume instrument with patent-pending NeuralHarmonics(TM),Technology. Small Child ... noninvasively on children weighing less than 60 pounds ... same instrument used for adult,patients. This enhanced BladderScan(R) ...
... German . , Malignant tumors have usually ... death, or apoptosis. Therefore, tumors are often resistant to ... forcing tumor cells to commit suicide. , This ... of the numerous molecular switches regulating the self-destruction process. ...
Cached Medicine News:Health News:Magnesium May Lower Risk for Some Strokes in Male Smokers 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 3Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 2Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 3Health News:Paradigm shift: Switch for programmed cell death promotes spread of glioblastoma 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Medicine Products: